Ataxia - Pipeline Insights, Recent Developments, Major Players and Review

Ataxia is a medical condition for the loss of muscular coordination when a voluntary movement is undertaken. From walking to picking up an object to swallowing, it can impact any activity that requires muscles to cooperate to complete a function. Uncoordinated muscle movements induce ataxia, which results in poor balance, a staggering stride, trouble sitting, and/or sloppy movements. The medical condition is caused by different ailments, such as a brain tumor, a head injury, a stroke, or excessive alcohol consumption.

Genetic infantile ataxia has a prevalence of 0.1 to 10 occurrences per 100,000 people. Although some varieties of congenital ataxia can lower a person's life expectancy, many people with the disorder live as long as those who do not. If ataxia arises due to an accident, surgery, or disease, it may stabilize or improve with time, but it may also deteriorate. However, in many situations, timely treatment for acquired ataxia can lead to a positive outcome and even the reversal of the illness.

Report Key Takeaways

Recommended Medications/Treatments for Ataxia

A healthcare physician may recommend a specific treatment strategy to address one of the ataxia symptoms:

Medications

Ataxia symptoms can be cured with the help of certain drugs. Amitriptyline or gabapentin for nerve pain, antidepressants for depression, and muscle relaxants for cramps or stiffness are a few examples.

Tremors and Muscle Spasms

A healthcare expert may recommend different medications and physical therapy to assist the patient in increasing mobility and finding new ways to complete chores.

Speech Therapy

A speech therapist can assist with communication problems and muscle control concerns such as coughing, choking, and swallowing. In addition, a speech therapist can help the person learn how to utilize speech aids if necessary.

Recent Developments Related to Ataxia

  • Reata Pharmaceuticals Inc. has received approval for a new medication application for omaveloxolone to treat priority evaluation of Friedreich's ataxia. The NDA is backed up by favorable safety and efficacy results from the MOXIe part 2 trial and supportive data from the MOXIe part 1 and MOXIe extension trials, according to a company.
  • Top-line data from a Phase 3 clinical trial examining the efficacy and safety of Biohaven Pharmaceutical Holding Company Ltd.'s experimental treatment, troriluzole, in patients with spinocerebellar ataxia has been released (SCA). Given the severity of the disease, the company is looking forward to sharing SCA3 genotyping data with regulators and collaborating with the FDA to address the significant unmet need in this patient population.
  •  The US Food and Drug Administration has approved the New Drug Application for LX2006 developed by LEXEO Therapeutics' Investigational. Friedreich's ataxia-cardiomyopathy is an AAV-based gene therapy candidate for treating Friedreich's ataxia cardiomyopathy.

Major Players Working on Ataxia

Vico Therapeutics, Seelos Therapeutics, uniQure, Biohaven Pharmaceuticals, Ionis Pharmaceuticals, and Takeda Pharmaceutical Company Limited are some of the leading companies across the globe that are working on the research and development of ataxia therapies.

PrivacyPrivacy Facebook Twitter Linkedin Reddit Word to Clean HTML ConverterWord Editor HTML Undo New page indentation compress encoding option ico option2 option3 option4 option5 option6 option7 option8Clean

Key Reasons to Purchase This Report

  • The pipeline insight's primary goal is to provide accurate information about beneficial therapies and pharmaceuticals for ataxia patients and review recent results.
  • An overview of the latest medications related to ataxia in different development phases, as well as information on the leading companies globally developing the drugs.
  • Based on industry experts' most validated data, an in-depth overview of the most recent clinical procedures and treatment trials in various parts of the world.

Key Reasons to Purchase This Report

  • The pipeline insight's primary goal is to provide accurate information about beneficial therapies and pharmaceuticals for ataxia patients and review recent results.
  • An overview of the latest medications related to ataxia in different development phases, as well as information on the leading companies globally developing the drugs.
  • Based on industry experts' most validated data, an in-depth overview of the most recent clinical procedures and treatment trials in various parts of the world.

Frequently asked questions about the global Ataxia industry

A genetic abnormality can induce ataxia, or it can be acquired as a result of an anatomical injury to the cerebellum or spinal cord.

Ataxia symptoms vary depending on the type of ataxia and the age of the patient who has been diagnosed with this medical disease.

A person who exhibits signs of ataxia will almost certainly be referred to a neurologist, a doctor who specializes in nervous system disorders. The neurologist will look over the person's medical history to see if there are any plausible causes, as well as their family history for signs of inherited ataxia.

Ataxia is a condition in which the ability to coordinate voluntary motions is lost. The limbs, trunk, neck, and head, as well as breathing, swallowing, language, the pharynx, and larynx, and other structures, may be affected.

The recovery time required for the patient having ataxia depends on the patient type. The patient can recover completely if the source of the ataxia is target early and totally cured.

Choose License Type
Published Date:  Jun 2022
Category:  Pharmaceuticals
Report ID:   60575
Report Format:   PDF
Pages:   90
Rating:    4.8 (16)
Connect With Us
+1-408-641-3282
24/7 Research Support